Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Angiotensin II Receptor Blockers (ARB) on Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Odense University Hospital.
Recruitment status was:  Active, not recruiting
Information provided by:
Odense University Hospital Identifier:
First received: February 21, 2006
Last updated: June 26, 2009
Last verified: June 2009

The consequence of aortic valve stenosis (AVS) is increased pressure load on the left ventricle which causes left ventricular (LV) hypertrophy, and myocardial stretch will cause activation of cardiac peptides and activation of the renin angiotensin aldosterone system (RAAS). The consequence of LV hypertrophy is increased chamber-stiffness and delayed active LV relaxation which initially will cause diastolic and later systolic dysfunction. In heart failure (HF) and ischemic heart disease the degree of diastolic dysfunction has been demonstrated to correlate with functional class, neurohormonal activation and prognosis which also recently have been suggested for AVS.

With longstanding elevated filling pressures the left atrium (LA) will dilate. Only limited data are available on the degree and importance of LA dilatation in AVS.

When apparent, symptoms of HF in AVS are associated with high mortality rates. If LV systolic dysfunction also is present prognosis will deteriorate further. In these cases aorta valve replacement (AVR) is recommended. AVR will normalize pressure overload and thereby decreases LV hypertrophy. Previously it was believed that in time LV hypertrophy regressed towards normal and even normalized. Recent studies however have demonstrated that LV hypertrophy regression mainly happens during the first year after AVR, and little subsequent changes are seen during the remaining 10 years. Furthermore, patients that experience most regression of hypertrophy have more favourable outcome and better functional class than patients with less regression of hypertrophy. Thus absence of reverse remodelling is associated with poor outcome after AVR. Importantly the regression of LV hypertrophy is closely paralleled by decreasing RAAS hyperactivity.

RAAS hyperactivity may be attenuated pharmacologically with angiotensin II receptor blockers (ARB) which in systemic hypertension with LV hypertrophy has been associated with reverse remodelling.

The hypothesis is that in patients undergoing AVR for symptomatic AVS, 12 months post operative blockade of the angiotensin II receptor will accelerate LV and LA reverse remodelling, reduce filling pressures and suppress neurohormonal activation compared with conventional therapy. This will lead to improved exercise tolerance and due to improved left atrial function reducing the risk of atrial arrythmias.

Condition Intervention Phase
Aortic Valve Stenosis
Left Ventricular Hypertrophy
Atrial Fibrillation
Drug: Candesartan
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Left Ventricular Reverse Remodelling After Aortic Valve Replacement in Severe Valvular Aortic Stenosis - Effect of Blockade of the Angiotensin-II Receptor

Resource links provided by NLM:

Further study details as provided by Odense University Hospital:

Primary Outcome Measures:
  • LV mass index
  • LA volume index
  • Plasma nt-pro BNP concentration

Secondary Outcome Measures:
  • Diastolic E/e' ratio
  • Overall LV function assessed by the Doppler echocardiographic Tei Index
  • Regional LV function assessed with tissue Doppler imaging
  • LV end systolic and end diastolic volume index
  • Atrial arrhythmias assessed with 48h Holter after 12 months
  • Exercise capacity after 12 months
  • Serial changes in LV diastolic, overall LV function and regional LV systolic function
  • Assess serial changes in plasma nt-pro BNP, ANP, and renin

Estimated Enrollment: 140
Study Start Date: February 2006
Estimated Study Completion Date: June 2009
Estimated Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Symptomatic severe AVS referred for valve replacement (mechanic prosthesis or bioprosthesis) at Odense University Hospital
  2. Signed informed consent

Exclusion Criteria:

  1. Severe renal failure (s-creatinine >300 mmole/l)
  2. Moderate or severe hepatic failure
  3. Moderate or severe LV systolic dysfunction (LVEF<40%)
  4. Patients already treated with ACE-I or ARB
  5. Known intolerance for ARB
  6. Unwilling to participate in the study
  7. Poor echocardiographic window
  8. Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00294775

Cardiology Department, Odense University hospital
Odense, Fyn, Denmark, 5000
Sponsors and Collaborators
Odense University Hospital
Study Director: Torben Haghfelt, Md, DMSc Kardiologisk forskningsenhed, OUH
Principal Investigator: Jordi S Dahl, MD, MMSci Kardiologisk forskningsenhed, OUH
Study Chair: Henrik Nissen, MD, PhD Kardiologisk forskningsenhed, OUH
Study Chair: Jacob E Moller, Md, Ph.D Kardiologisk forskningsenhed, OUH
Study Chair: Lars Videbæk, MD, Ph.d Kardiologisk forskningsenhed, OUH
Study Chair: Lars I Andersen, MD, DMSc Department of thoracic surgery, OUH
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00294775     History of Changes
Other Study ID Numbers: EudraCT number 2005-001930-34
Study First Received: February 21, 2006
Last Updated: June 26, 2009

Keywords provided by Odense University Hospital:
diastolic dysfunction
Reverse Remodelling

Additional relevant MeSH terms:
Aortic Valve Stenosis
Atrial Fibrillation
Constriction, Pathologic
Hypertrophy, Left Ventricular
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Pathological Conditions, Anatomical
Heart Valve Diseases
Ventricular Outflow Obstruction
Angiotensin Receptor Antagonists
Angiotensin II
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors processed this record on April 24, 2017